GlassScriptPhysician profile
Michael S Buchholtz
NPI 1861467425
$1,212.46
in general payments reported to CMS, 2019-2025
28 companies · $154 in 2025
The $154 reported for 2025 was less than what a typical Hematology (Internal Medicine) provider received nationally (typical 2025 total: $1,177).
See the full distribution for Hematology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $185 · 2020: $85.86 · 2021: $288 · 2022: $221 · 2023: $188 · 2024: $89.80 · 2025: $154.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $399 · Education: $33.34.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $398.56 |
| Education | $33.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $249.21 | 2019-2023 | |
| Abbvie INC. | $143.14 | 2021-2023 | Qulipta, Ubrelvy, Venclexta |
| Astellas Pharma US INC | $87.30 | 2019-2025 | Padcev |
| Glaxosmithkline, LLC. | $71.03 | 2020-2022 | |
| Janssen Biotech, INC. | $59.04 | 2019-2025 | Rybrevant |
| Alexion Pharmaceuticals, INC. | $47.87 | 2019-2021 | |
| Sumitomo Pharma America, INC. | $39.46 | 2024-2025 | Orgovyx |
| Pfizer INC. | $39.33 | 2020-2024 | |
| Emd Serono, INC. | $39.23 | 2019-2023 | Mavenclad |
| Genentech USA, INC. | $38.93 | 2019-2022 | |
| Dendreon Pharmaceuticals LLC | $34.16 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $32.25 | 2022 | |
| Menarini Silicon Biosystems, INC. | $29.48 | 2023-2024 | Cellsearch |
| Myovant Sciences INC. | $28.85 | 2021 | |
| Pharmacyclics LLC, An Abbvie Company | $28.80 | 2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Springworks Therapeutics, INC. | $28.53 | 2024 | Ogsiveo |
| Epizyme, INC. | $28.00 | 2022 | |
| Rigel Pharmaceuticals, INC. | $25.15 | 2025 | Tavalisse, Rezlidhia, Gavreto |
| Puma Biotechnology, INC. | $20.28 | 2022 | |
| Aurinia Pharma U.S., INC. | $19.91 | 2025 | Lupkynis |
| Merck Sharp & Dohme LLC | $18.09 | 2024 | Keytruda |
| Beigene USA, INC. | $17.95 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $17.21 | 2025 | |
| Beone Medicines USA, INC. | $15.25 | 2025 | Brukinsa |
| Ethicon US, LLC | $14.70 | 2019 | |
| Adaptive Biotechnologies Corporation | $14.25 | 2022 | |
| Seagen INC. | $13.14 | 2023 | Adcetris |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Buchholtz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.